3.3.2.6: leukotriene-A4 hydrolase
This is an abbreviated version!
For detailed information about leukotriene-A4 hydrolase, go to the full flat file.
Word Map on EC 3.3.2.6
-
3.3.2.6
-
5-lipoxygenase
-
arachidonic
-
epoxide
-
medicine
-
leukocyte
-
asthma
-
bestatin
-
chemoattractant
-
eicosanoids
-
metalloenzyme
-
flap
-
ionophore
-
alox5ap
-
tuberculous
-
transcellular
-
5-lipoxygenase-activating
-
aminopeptidases
-
captopril
-
lipoxins
-
pro-gly-pro
-
montelukast
-
proline-glycine-proline
-
5-hete
-
zileuton
-
diagnostics
-
pharmacology
-
drug development
- 3.3.2.6
-
5-lipoxygenase
-
arachidonic
- epoxide
- medicine
- leukocyte
- asthma
- bestatin
-
chemoattractant
-
eicosanoids
-
metalloenzyme
- flap
-
ionophore
-
alox5ap
-
tuberculous
-
transcellular
-
5-lipoxygenase-activating
- aminopeptidases
- captopril
-
lipoxins
- pro-gly-pro
- montelukast
- proline-glycine-proline
-
5-hete
- zileuton
- diagnostics
- pharmacology
- drug development
Reaction
Synonyms
EH, epoxide hydrolase, hydrolase, leukotriene A4, leukotriene A(4) hydrolase, leukotriene A4 hydrolase, leukotriene A4 hydrolase/aminopeptidase, leukotriene hydrolase A4, leukotriene-A4 hydrolase, leukotriene-A4-hydrolase, LT A4 hydrolase, LTA-4 hydrolase, LTA4 hydrolase, LTA4-h, LTA4H, More
ECTree
Advanced search results
Application
Application on EC 3.3.2.6 - leukotriene-A4 hydrolase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
diagnostics
drug development
medicine
pharmacology
-
LTA4H genes are risk factors for asthma in two different ethnic groups, individuals from Mexico and Puerto Rico
diagnostics
LTB4 can serve as a biomarker for evaluating bestatin efficacy in colorectal cancer and the antitumor effects of bestatin through its targeting of LTA4H
development of LTA4H inhibitors in cancer prevention and therapy
drug development
Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis
drug development
drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis. Inhibiting LTB4 biosynthesis and subsequently neutrophilic inflammation may provide a potential strategy for the treatment of acute lung injury (ALI) and idiopathic pulmonary fibrosis (IPF)
drug development
possible therapeutic potential of targeting LTB4/BLT signaling in asthma, but production of LTB4 may not be responsible for airway neutrophils in severe asthma
drug development
the bifunctional enzyme is a target for development of selective inhibitors
-
the lipid metabolic activity of enzyme plays a central role in the control of polymorphonuclear leukocyte function and in the development of inflammation, the regulation of enzyme presents a novel potential target for anti-inflammatory therapy
medicine
-
enzyme overexpression appears to be an early event in esophageal adenocarcinogenesis and is a potential target for the chemoprevention of esophageal adenocarcinogenesis
medicine
enzyme overexpression appears to be an early event in esophageal adenocarcinogenesis and is a potential target for the chemoprevention of esophageal adenocarcinogenesis
medicine
-
the product is a classical chemoattractant, triggers adherence and aggregation of leukocytes to the endothelium, modulates immune responses, participates in the host-defence against infections and is a mediator of PAF-induced lethal shock
medicine
-
the product is a classical chemoattractant, triggers adherence and aggregation of leukocytes to the endothelium, modulates immune responses, participates in the host-defence against infections and is a mediator of PAF-induced lethal shock
medicine
-
the product is a classical chemoattractant, triggers adherence and aggregation of leukocytes to the endothelium, modulates immune responses, participates in the host-defence against infections and is a mediator of PAF-induced lethal shock
medicine
-
the product is a classical chemoattractant, triggers adherence and aggregation of leukocytes to the endothelium, modulates immune responses, participates in the host-defence against infections and is a mediator of PAF-induced lethal shock
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
-
the enzyme catalyses the hydrolysis of leukotriene A4 into the proinflammatory substance leukotriene B4
medicine
findings suggest that agents affecting LTB4 biosynthetic pathway may prove useful for primary or secondary prevention of heart attacks
medicine
-
LTA4H appears to be a promising target for development of drugs for prevention and treatment of atherosclerosis and its associated thrombotic complications
medicine
-
LTA4H appears to be a promising target for development of drugs for prevention and treatment of atherosclerosis and its associated thrombotic complications
medicine
-
the 5-Lox/LTA4H pathway is involved in 7,12-dimethylbenz[alpha]anthracene induced oral carcinogenesis and may be targeted for chemoprevention of oral cancer
medicine
-
understanding the molecular alterations that influence primary effusion lymphoma development will aid in the identification of novel therapeutic targets, as well as potential risk factors for this desease
medicine
-
inhibition of LTB4 synthesis may be beneficial in the treatment of severe asthma and viral exacerbations of asthma, in which neutrophilic inflammation is more prominent
medicine
-
inhibition of this enzyme can be a valid method in the treatment of inflammatory response exhibited through leukotriene B4
medicine
LTB4 can serve as a biomarker for evaluating bestatin efficacy in colorectal cancer and the antitumor effects of bestatin through its targeting of LTA4H
-
inhibition of LTA4H is a potential therapeutic strategy that can modulate key aspects of asthma
pharmacology
leukotriene 4 hydrolase is a key target for the treatment of cardiovascular disease
pharmacology
-
inhibition of LTA4H is a potential therapeutic strategy that can modulate key aspects of asthma
-